Select a Region North America


Andrew Therrien, PhD



Consulting (Strategy Management & Regulatory), Consulting (Strategy Management and HTA requirements), Pricing, Reimbursement & Market Access, Product Launch, Project Management, Research & Insights

Andy is a Consultant at EVERSANA MANAGEMENT CONSULTING with a background in chemistry, chemical engineering and life sciences consulting.

Prior to joining EVERSANA, Andy was a consultant at EQUITAS Life Sciences, where he helped to design and execute full product launch management, including pricing, go-to-market strategy and commercial launch training. Additionally, Andy has applied his educational expertise to support commercial excellence, learning engagement and training curriculum design in the pharmaceutical industry.

Andy’s laboratory research experience as a doctoral student in chemistry at Tufts University and chemical engineering as a post-doctoral scholar at UC–Santa Barbara has resulted in 24 peer-reviewed publications. His scientific research was focused on the fields of catalysis, nanotechnology and plasmonics. Andy’s academic achievements demonstrate his passion for learning, comfort with ambiguity and solution-oriented mindset.

Articles by Andrew Therrien, PhD

Critical Success Factors for Launching Products with Orphan Drug Designation

The Orphan Drug Act (ODA) was passed in 1983 to financially incentivize pharmaceutical companies to develop drugs for rare diseases or conditions, defined as a disease or condition that affects less than 200,000 people in the US.1 The financial incentives offered by the ODA are substantial and include tax credits up to 50% of the qualified clinical testing expenses for the taxable year, waived Prescription Drug User Fee Act (PDUFA) user fees that may be upwards of $3 million in 2022, and an extended market exclusivity period of seven years after approval.2 A recent analysis found that receiving an orphan drug designation does, on average, positively impact companies’ value as […]

Breaking through Barriers: Critical Success Factors for Launching Products with Breakthrough Therapy Designation

The FDA’s Breakthrough Therapy Designation (BTD) expedites patient access to innovative new treatments. While speeding up these processes can get new drugs to patients in need faster than they normally would through standard tracks, limited clinical evidence at launch and a compressed launch timeline can present stumbling blocks and uncertainties for commercialization teams tackling launch strategy, planning and execution. A differentiated product will contribute to broader adoption in the marketplace, but that is not the sole factor determining its success. Launch teams must understand that they can control and shape the product’s trajectory. Download the white paper to learn more about the implications of launching BTD products and some critical […]

Interested in scheduling a meeting or speaking event?


  • このフィールドは入力チェック用です。変更しないでください。